Fighting the FDA’s Final Rule on LDTs
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
Top of the News-lir
Subscribe today for access to
Articles and Reports
Getting Started with the FDA’s New LDT Rule
Experts explain what the phase-in process will look like—and how labs can get ahead of the game.
Transitioning the Clinical Lab
What clinical laboratory professionals need to know about healthcare provision for transgender and nonbinary patients
Crosswalked Codes in 2017 Clinical Laboratory Fee Schedule
...
Already a member? Log in here
Convergence: Diagnostics are Key to Life Sciences Innovation and Health Care Service Delivery
From - Laboratory Industry Report
Attendees at G2 Intelligence's 34th annual Lab Institute were treated to a history lesson about diagnostics as well as…
Singulex Assay Could ID Declining Cardiac Health
From - Laboratory Industry Report
An assay developed by a California-based laboratory that determines the levels of troponin could be used as a…
LabCorp Continues Shopping Spree by Acquiring ClearPath Diagnostics
...
Already a member? Log in here
Theranos Closes Labs to Focus on Technology
...
Already a member? Log in here
Randox Labs Introduces Alzheimer’s Genetic Test
...
Already a member? Log in here
OIG Addresses Status of PAMA Implementation
From - Laboratory Industry Report
Changes to Medicare Part B payment for lab tests mandated by the Protecting Access to Medicare Act of 2014 (PAMA) take effect on…
DEA’s Takeback Initiative Coincides with Quest Survey Highlighting Misuse of Prescription Drugs
From - Laboratory Industry Report
The U.S. Drug Enforcement Administration's latest National Take-Back Initiative happens this month on Oct. 22, when the public is…
Quest Says Many Americans Are Misusing or Abusing Prescription Drugs
...
Already a member? Log in here